Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Danaher (DHR) PT Raised to $125 at Baird
February 26, 2019 9:15 AM ESTBaird analyst Richard Eastman raised the price target on Danaher (NYSE: DHR) to $125.00 (from $114.00) while maintaining an Outperform rating following the announced GE Biopharma acquisition. Eastman views the acquisition as attractive.
Adjusting for ~$1.4B in NPV tax benefits to DHR, the purchase price... More
General Electric (GE) Adds to Gains Following BioPharma Deal, Up 18%
February 25, 2019 8:09 AM ESTGeneral Electric (NYSE: GE) Adds to Gains Following BioPharma Deal, Up 18%
... MoreGeneral Electric (GE) Jumps 7% on BioPharma Sale
February 25, 2019 7:13 AM ESTGeneral Electric (NYSE: GE) gains 7% after selling is BioPharma Business to Danaher (DHR) for $21.4 billion.
... More